Sera Whitelaw1, Kristen Sullivan2, Yousif Eliya1, Mohammad Alruwayeh2, Lehana Thabane1, Clyde W Yancy3, Roxana Mehran4, Mamas A Mamas5,6, Harriette G C Van Spall1,2,7,8. 1. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. 2. Department of Medicine, McMaster University, Hamilton, Canada. 3. Department of Medicine, Northwestern University, Chicago, IL, USA. 4. Ican School of Medicine, Mount Sinai Hospital, NY, New York, USA. 5. Institute of Population Health, University of Manchester, Manchester, UK. 6. Keele Cardiac Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, UK. 7. Population Health Research Institute, Hamilton, Canada. 8. ICES, McMaster University, Hamilton, Canada.
Abstract
AIMS: To evaluate temporal trends in the enrolment of females in randomized controlled trials (RCTs) of heart failure with reduced ejection fraction (HFrEF) published in high-impact journals, and assess RCT characteristics associated with under-enrolment. METHODS AND RESULTS: We searched MEDLINE, EMBASE and CINAHL for studies published from January 2000 to May 2019 in journals with impact factor ≥10. We included RCTs that recruited adults with HFrEF. We used a 20% threshold below the sex distribution of HFrEF to define under-enrolment. We used multivariable logistic regression to assess trial characteristics independently associated with under-enrolment. We included 317 RCTs. Among the 183 097 participants, mean (standard deviation) age was 63.0 (7.0) years and 25.5% were female. Females were under-enrolled in 71.6% [95% confidence interval (CI) 66.6-76.6%] of the RCTs; enrolment did not increase significantly between 2000-2019. Sex-related eligibility criteria [odds ratio (OR) 2.05, 95% CI 1.01-4.16; P = 0.046]; recruitment in ambulatory settings (OR 2.56, 95% CI 1.37-4.81; P = 0.003); trial coordination in North America (OR 4.44, 95% CI 1.09-18.07; P = 0.037), Europe (OR 6.79, 95% CI 1.63-27.39; P = 0.018) and Asia (OR 9.33, 95% CI 1.40-12.40; P = 0.033); drug (OR 1.76, 95% CI 1.96-7.36; P < 0.001) and device/surgical interventions (OR 1.69, 95% CI 1.16-9.43; P = 0.002); and men in first and last authorship position (OR 1.32, 95% CI 1.12-3.54; P = 0.047) were associated with under-enrolment of females. CONCLUSIONS: Females were under-enrolled relative to disease distribution in a majority of high-impact HFrEF RCTs, with no change in temporal trends between 2000 and 2019. Trial characteristics and gender of trial leaders were associated with under-enrolment.
AIMS: To evaluate temporal trends in the enrolment of females in randomized controlled trials (RCTs) of heart failure with reduced ejection fraction (HFrEF) published in high-impact journals, and assess RCT characteristics associated with under-enrolment. METHODS AND RESULTS: We searched MEDLINE, EMBASE and CINAHL for studies published from January 2000 to May 2019 in journals with impact factor ≥10. We included RCTs that recruited adults with HFrEF. We used a 20% threshold below the sex distribution of HFrEF to define under-enrolment. We used multivariable logistic regression to assess trial characteristics independently associated with under-enrolment. We included 317 RCTs. Among the 183 097 participants, mean (standard deviation) age was 63.0 (7.0) years and 25.5% were female. Females were under-enrolled in 71.6% [95% confidence interval (CI) 66.6-76.6%] of the RCTs; enrolment did not increase significantly between 2000-2019. Sex-related eligibility criteria [odds ratio (OR) 2.05, 95% CI 1.01-4.16; P = 0.046]; recruitment in ambulatory settings (OR 2.56, 95% CI 1.37-4.81; P = 0.003); trial coordination in North America (OR 4.44, 95% CI 1.09-18.07; P = 0.037), Europe (OR 6.79, 95% CI 1.63-27.39; P = 0.018) and Asia (OR 9.33, 95% CI 1.40-12.40; P = 0.033); drug (OR 1.76, 95% CI 1.96-7.36; P < 0.001) and device/surgical interventions (OR 1.69, 95% CI 1.16-9.43; P = 0.002); and men in first and last authorship position (OR 1.32, 95% CI 1.12-3.54; P = 0.047) were associated with under-enrolment of females. CONCLUSIONS: Females were under-enrolled relative to disease distribution in a majority of high-impact HFrEF RCTs, with no change in temporal trends between 2000 and 2019. Trial characteristics and gender of trial leaders were associated with under-enrolment.
Authors: Jie Wei Zhu; NhatChinh Le; Sunny Wei; Liesl Zühlke; Renato D Lopes; Faiez Zannad; Harriette G C Van Spall Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-09-05
Authors: Muhammad Shariq Usman; Harriette G C Van Spall; Stephen J Greene; Ambarish Pandey; Darren K McGuire; Ziad A Ali; Robert J Mentz; Gregg C Fonarow; John A Spertus; Stefan D Anker; Javed Butler; Stefan K James; Muhammad Shahzeb Khan Journal: Nat Rev Cardiol Date: 2022-05-17 Impact factor: 49.421
Authors: Monica Parry; Harriette G C Van Spall; Kerri-Anne Mullen; Sharon L Mulvagh; Christine Pacheco; Tracey J F Colella; Marie-Annick Clavel; Shahin Jaffer; Heather J A Foulds; Jasmine Grewal; Marsha Hardy; Jennifer A D Price; Anna L E Levinsson; Christine A Gonsalves; Colleen M Norris Journal: CJC Open Date: 2022-04-19
Authors: Ersilia M DeFilippis; Melvin Echols; Philip B Adamson; Wayne B Batchelor; Lauren B Cooper; Lawton S Cooper; Patrice Desvigne-Nickens; Richard T George; Nasrien E Ibrahim; Mariell Jessup; Dalane W Kitzman; Eric S Leifer; Martin Mendoza; Ileana L Piña; Mitchell Psotka; Fortunato Fred Senatore; Kenneth M Stein; John R Teerlink; Clyde W Yancy; JoAnn Lindenfeld; Mona Fiuzat; Christopher M O'Connor; Orly Vardeny; Muthiah Vaduganathan Journal: JAMA Cardiol Date: 2022-05-01 Impact factor: 30.154
Authors: Erin D Michos; Tina K Reddy; Martha Gulati; LaPrincess C Brewer; Rachel M Bond; Gladys P Velarde; Alison L Bailey; Melvin R Echols; Samar A Nasser; Harold E Bays; Ann Marie Navar; Keith C Ferdinand Journal: Am J Prev Cardiol Date: 2021-08-20